MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Biomarkers of rapid progression of cognitive decline in Parkinson’s disease

S. Martinez-Horta, F. Sampedro, J. Pagonabarraga, J. Marin-Lahoz, A. Horta-Barba, H. Bejr-Kasem, I. Aracil, J. Perez-Perez, MA. Boti, J. Kulisevsky. (Barcelona, Spain)

Meeting: 2018 International Congress

Abstract Number: 1272

Keywords: Cognitive dysfunction, Dementia, Executive functions

Session Information

Date: Monday, October 8, 2018

Session Title: Parkinson's Disease: Cognition

Session Time: 1:15pm-2:45pm

Location: Hall 3FG

Objective: We aimed to explore cross-sectional grey-matter volume (GMV) and CSF biomarkers differences in PD patients exhibiting a rapid progression of cognitive decline compared to those showing a stable course in a 2-year follow-up.

Background: Cognitive impairment is an essential feature of Parkinson’s disease (PD) which exhibits a variable course. Whereas cognitive status remains relatively stable in some patients, it rapidly evolves to dementia in others. Hence, identifying early biomarkers of rapid progression of cognitive decline represents an urgent need.

Methods: From the Parkinson’s Progression Markers Initiative (PPMI), we identified a homogenous sample of fifty idiopathic, de-novo PD patients with preserved cognitive function (MoCA>27). The sample was grouped as those who remained cognitively stable (n=30) and those who converted to PD-MCI (n=20) in a 2-year follow-up. Groups where matched for age, education, cognition, mood, UPDRS-III and H&Y stage. CSF values of TAU/pTAU, α-synuclein and Aβ-42 were recorded. A VBM of GMV was performed. Between-group comparison was done using age, sex and education as nuisance variables. Regression analysis was performed between the identified clusters of GMV, CSF biomarkers and rate of annual MoCA change.

Results: No between group differences were found in clinical/sociodemographic measures. At baseline, converters showed a significant decrease of posterior-cortical GMV mostly ascribed to the bilateral inferior occipital gyrus, bilateral angular gyrus, bilateral middle and right inferior temporal and frontal gyrus. GMV values in the left angular gyrus (r=0.512;p<0.001), the right visual-association area (r=0.391;p>0.01), the right middle temporal gyrus (r=0.426;p<0.01) and the right inferior frontal gyrus (r=0.449;p<0.01) appeared strongly associated with more severe cognitive change. Increased TAU was associated with decreased GMV in left angular gyrus (r=-0.449;p<0.001), bilateral visual-association areas (r=-0.346;p<0.01), inferior (r=-0.340;p<0.01) and middle temporal gyrus (r=-0.313p<0.01) and higher rate of cognitive decline (r=-0.318;p<0.01).

Conclusions: In de-novo PD, early posterior-cortical changes and related increased TAU pathology appears predictive to rapid cognitive decline. It highlights the relevance of posterior-cortical deficits as biomarkers of more aggressive forms of cognitive deterioration in this population.

To cite this abstract in AMA style:

S. Martinez-Horta, F. Sampedro, J. Pagonabarraga, J. Marin-Lahoz, A. Horta-Barba, H. Bejr-Kasem, I. Aracil, J. Perez-Perez, MA. Boti, J. Kulisevsky.. Biomarkers of rapid progression of cognitive decline in Parkinson’s disease [abstract]. Mov Disord. 2018; 33 (suppl 2). https://www.mdsabstracts.org/abstract/biomarkers-of-rapid-progression-of-cognitive-decline-in-parkinsons-disease/. Accessed June 15, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/biomarkers-of-rapid-progression-of-cognitive-decline-in-parkinsons-disease/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley